|
|
Countries covered: United States
With medicines moving closer to deciphering the root cause of illness, imaging technologies focusing on detecting and characterizing the biological basis of disease will become critical. As this medical trend continues, market growth will be attributed to dedicated positron emission tomography (PET), which is emerging as a superior imaging tool, capable of highlighting tumors that were possibly undetected by traditional imaging modalities. This Frost & Sullivan research provides the current state of the U.S. nuclear medicine markets, including the PET scanner and gamma camera sectors. By identifying changing reimbursement regulations and making strategic recommendations, this comprehensive information allows your firm to take advantage of key opportunities in this dynamic field. Expanding Reimbursement Policy Boosts PET Scanner Revenues "The dedicated PET market had it most successful year in 2000," say the authors of this research. "Sales were phenomenal, with indication that this extremely positive trend is only the beginning of what will shape up to be a robust market." The availability of reimbursement for PET procedures has been the single most significant driver the industry has witnessed since its inception. Between 1998 and 2000, coverage for dedicated PET scans have expanded to include 12 new procedures. The majority of reimbursements are for cancer detection applications since PET scanners are now used more frequently by the medical community. Gamma Camera Finds Niche in Cardiac Imaging Nuclear cardiography is clearly sustaining the gamma camera market's current expansion. Single photon emissions computer tomography (SPECT) now holds a central role in functional cardial perfusion studies, with as many as 85 percent of myocardial procedures being done with SPECT. "The rapid rise in SPECT utilization in the last decade bears adequate witness to the fact that this technology is both sensitive and specific enough to make other modalities for cardiac imaging relatively superfluous. In terms of cost effectiveness, perhaps only PET can supersede it in the long-term," state the authors. This Frost & Sullivan research provides in-depth market intelligence, enabling your company to evaluate the current state of the U.S. nuclear medicine industry and devise the winning strategy to help maximize your bottom line. |
Additional Information
Market Participants
ADAC Laboratories, Inc.
CTI PET Systems, Inc.
Digirad Corp.
Digital Scintigraphics, Inc.
Fischer Imaging Corp.
Gamma Medica, Inc.
GE
Marconi Corp. Plc
NeuroPhysics Corp.
Positron Corp.
Siemens AG
Toshiba Medical Systems
Related Companies
ABC Laboratories, Inc.
Affymax Research Institute
Amersham Plc
Biodex Medical Systems
Bracco Diagnostics, Inc.
Burle Industries, Inc.
Data Spectrum Corp.
GlaxoSmithKline
IBA/Eastern Isotopes, Inc.
IS2 Research, Inc.
Isotope Products Laboratory
Kodak Canada, Inc.
Mallinckrodt, Inc. / Tyco
MDS Nordion
P.E.T.Net Pharmaceuticals, Inc.
Synpro/Delpro Ltd.
Associations
Academy of Molecular Imaging
Society of Nuclear Medicine
More United States Oncology/Hematology Reports
2012 US Tumor Marker Testing Market Outlook: Growth Opportunities and Strategies by
Venture Planning Group
Highlights Comprehensive 620-page analysis of the US tumor marker testing market. Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social ...
The 2012 Cancer Diagnostics Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers by
Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...
The 2012 US Cancer Diagnostics Market by
Venture Planning Group
This report presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory practice, as well as key economic, ...
The 2012 CA Tumor Markers: US, Europe, JapanTest Volume, Sales Forecasts and Supplier Shares by Country by
Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...
Abraxane (Breast Cancer) - Analysis and Forecasts to 2020 by
GlobalData
Abraxane (Breast Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Abraxane (Breast Cancer) - Analysis and Forecasts to 2020” provides Abraxane sales forecasts for ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>